Overview

• U.S. biopharma firm's Q1 net income rose to $24.1 mln from a loss last year

• Company reported $36.8 mln in Q1 revenue, mainly from a $20 mln license payment

• R&D and G&A expenses increased due to Phase 3 CATT1 trial investment

Outlook

• vTv expects Phase 3 CATT1 trial enrollment to complete in Q3 2026

• Company anticipates current cash will fund operations through CATT1 topline data readout

Result Drivers

• LICENSE PAYMENT - Q1 revenue and net income boosted by $20 mln upfront payment from Newsoara license amendment

• R&D SPENDING - Higher R&D expenses driven by continued investment in Phase 3 CATT1 trial

• G&A EXPENSES - Increased G&A expenses reflect ongoing support for corporate operations and clinical development

Company press release: ID:nGNX5N2BDV

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Operating Expenses		$13.58 mln
Q1 Operating Income		$23.26 mln

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for vTv Therapeutics Inc is $55.00, about 71.3% above its May 12 closing price of $32.11

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.